Relationship of adiponectin content in plasma with the lipid and carbohydrate metabolism in males

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

We studied the relationships between concentration in the blood of one of the adipokines - biologically active proteins, derived from adipose tissue, - adiponectin with parameters of carbohydrate and lipid metabolism in males. It was found that adiponectin level was mainly related to the serum content of nonesterified fatty acids (NEFA) and was its independent determinant.This association was negative and took place in patients both of normal and excessive body mass index. In these groups there was a negative relationship between the adiponectin level and frequency of type 2 diabetes also. But in according to the linear multiply regression analysis, the influence of adiponectin on frequency of this disease depended on presence in the model of NEFA and triglycerides.

Upon this data, we suggest that in males adiponectin influence mainly on the NEFA metabolism, and this influence can explain its antidiabetogenic effect.

About the authors

D. A. Tanjansky

Research Institute of Experimental Medicine of the RAMS

Author for correspondence.
Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

Е. М. Firova

Research Institute of Experimental Medicine of the RAMS

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

L. V. Shatilina

Research Institute of Experimental Medicine of the RAMS

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

A. D. Denisenko

Research Institute of Experimental Medicine of the RAMS

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

References

  1. Климов А. Н., Никульчева Н. Г. Обмен липидов и липопротеинов и его нарушения. СПб.: Питер Ком, 1999.
  2. Фирова Э. М., ТанянскийД. А., Денисенко А. Д. Уровень адипонектина у пациентов с метаболическим синдромом // Материалы научно-практической конференции «Современная кардиология: наука и практика» // Вести. СПбГМА им. И. И. Мечникова (приложение). 2007. № 2 (2). С. 184-185.
  3. Abbasi F, Chu J., Lamendola C. et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin // Diabetes. 2004. Vol. 53. P. 585-590.
  4. Allain C., Poon L., Chan C. et al. Enzymatic determination of total serum cholesterol // Clin. Chem. 1974. Vol. 20. P. 470-475.
  5. Arita Y., Kihara S., Ouchi N. et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity // Biochem. Biophys. Res. Commun. 1999. Vol. 257. № 1. P. 79-83.
  6. Borona E., Targher G., Alberiche M. et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity // Di¬abetes Care. 2000. Vol. 23. P. 57-63.
  7. Bruce C. R., Mertz V. A., Heigenhauser G. J. F., Dyck D. J. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects //Diabetes. 2005. Vol. 54. P. 3154-3160.
  8. Bucolo G., David H. Quantitative determination of serum triglycerides by the use of enzymes // Clin. Chem. 1973. Vol. 19. P. 476-482.
  9. Chandran M., Phillips S. A., Ciaraldi T., Henry R. R. Adiponectin: more just another fat cell hormone? // Diabetes Care. 2003. Vol. 26. P. 2442-2450.
  10. Chen M. B., McAinch A. J., Macaulay S. L. et al. Impaired activation of АМР-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics // J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 3665-3672.
  11. Chobanian A., Bakris G., Black H. et al. Seventh report of the Joint National Committee of prevention, detection, evaluation and treatment of high blood pressure // Hypertension. 2003. Vol. 42. P. 1206-1252.
  12. Choi К. M., Lee J., Lee K. W. et al. The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors // Eur. J. Endocrinol. 2004. Vol. 150. P. 715-718.
  13. Duncan В. B., Schmidt M. L, Pankow J. S. et al. Adiponectin and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study // Diabetes. 2004. Vol. 53. P. 2473-2478.
  14. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) //JAMA. 2001. Vol. 285. № 19. P. 2486-2497.
  15. Friedwald J, Levy R., Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparation ultracentrifuge //Clin. Chem. 1972. Vol. 18. P 499-509.
  16. Fruebis J., Tsao Т-S., Javorschi S. et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice // Proc. Natl. Acad. Sci. 2001. Vol. 98. P. 2005-2010.
  17. Gavrila A., Chan J. L., Yiannakouris N. et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies // J. Clin. En¬docrinol. Metab. 2003. Vol. 8 8. P. 4823-4831.
  18. Hanley A. J. G., Bowden D., Wagenknecht L. E. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic hispanics and african-americans // J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 2665- 2671.
  19. Hotta K., Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients // Arterioscler. Thromb. Vase. Biol. 2000. Vol. 20. P 1595-1599.
  20. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. 2005. http://www. idf. org/webdata/docs/Metabolic_ syndrome_definition. pdf.
  21. Lau D. С. W, Dhillon В., Yan H. et al. Adipokines: molecular links between obesity and atheroslcerosis //Am. J. Physiol. Heart Circ. Physiol. 2005. Vol. 288. P.H2031-H2041.
  22. Lewis G. E, Carpentier A., Adeli K., GiaccaA. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes // Endocrine Rev. 2002. Vol. 23. P. 201-229.
  23. Matsubara C., Nishikawa Y, Yoshida Y and Takamura K. A. Spectrophotometric method for the determination of free fatty acid in serum using acyl-coenzyme A synthetase and acyl-coenzyme A oxidase // Anal. Biochem. 1983. Vol. 130. P. 128-133.
  24. Nakashima R., Kamei N, Yamane K. et al. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in japanese-americans // J. Clin. Endocrinol. Metab. 2006. Vol. 91. P. 3 873-3 877.
  25. Paolisso G., Tataranni P. A., Foley J. E. et al. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM // Diabetologia. 1995. Vol. 38. P. 1213-1217.
  26. Salas-Salvado J., Granada M., Bullo M. et al. Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome // Metabolism. 2007. Vol. 56. P. 1486-1492.
  27. SilhaJ. V., Krsek M., Skrha J. V. et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance // Eur. J. Endocrinol. 2003. Vol. 149. P. 3 31-3 3 5.
  28. Tschritter O., Fritsche A., Thamer C. et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism // Diabetes. 2003. Vol. 5 2. P. 239-243.
  29. World Health Organization Report. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. WHO, Geneva, 1999.
  30. Yamauchi T, Kamon J., Waki H. et al. Globular adiponectin protected ob/ob mice from diabetes and apoE-deficient mice from atherosclerosis // J. Biol. Chem. 2003. Vol. 278. P. 2461-2468.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.